Acurx Pharmaceuticals, Inc. (ACXP) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Staten Island, NY, United States. The current CEO is David Luci.
ACXP has IPO date of 2021-06-25, 4 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $4.91M.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
